Axogen
Work Here?
About Axogen
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
IPO
Headquarters
Alachua, Florida
Founded
2002
Overview
Simplify's Take
What believers are saying
- AI-driven surgical solutions could enhance Axogen's market position.
- Personalized medicine trend allows Axogen to develop customized nerve repair solutions.
- Telemedicine rise enables Axogen to offer post-surgical care solutions.
What critics are saying
- Emerging biotech competition may impact Axogen's market share.
- FDA approval delays could affect Avance Nerve Graft's launch timelines.
- Stock dilution from public offering may affect shareholder value.
What makes Axogen unique
- Axogen leads in innovative surgical solutions for peripheral nerve injuries.
- Avive+ Soft Tissue Matrix offers unique temporary protection during nerve healing.
- Axogen's rolling BLA submission for Avance Nerve Graft marks a regulatory milestone.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$131.9M
Above
Industry Average
Funded Over
2 Rounds
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
Paid Vacation
Paid Holidays
Employee Stock Purchase Plan
Tuition Reimbursement
Paid Parental Leave
Paid Caregiver Leave
Basic Life Insurance
Supplemental Life Insurance
Disability Insurance
Company News
ALACHUA, Fla. and TAMPA, Fla., March 24, 2025 (GLOBE NEWSWIRE) - Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy.
ALACHUA, Fla. and TAMPA, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) - Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Craig Swandal as Vice President of Operations.
Dr. Peterson, an experienced clinical researcher with a background in both academic and industry roles, joins from Axogen, where he specialized in therapies for peripheral nerve repair.
Axogen names ex-abbott exec Michael Dale as CEO.
ALACHUA, Fla. and TAMPA, Fla., June 24, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announces the launch of its newest product, Avive+ Soft Tissue Matrix™. Avive+™ is intended for use as a soft tissue barrier and is a resorbable, multi-layer amniotic membrane allograft that provides temporary protection and tissue separation during the critical phase of peripheral nerve healing. Avive+ is processed and distributed in accordance with U.S. Food and Drug Administration (FDA) requirements for Human Cellular and Tissue-based Products (HCT/P) under 21 CFR Part 1271 regulations, U.S
Axogen is Hiring for 27 Jobs on Simplify!
Find jobs on Simplify and start your career today
IT & Security
1 Open Roles
Content & Writing
1 Open Roles
Legal & Compliance
2 Open Roles
Training
1 Open Roles
About Axogen
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
IPO
Headquarters
Alachua, Florida
Founded
2002
Axogen is Hiring for 27 Jobs on Simplify!
Find jobs on Simplify and start your career today
IT & Security
1 Open Roles
Content & Writing
1 Open Roles
Legal & Compliance
2 Open Roles
Training
1 Open Roles